BR112012006686A2 - composto amida substituído - Google Patents

composto amida substituído

Info

Publication number
BR112012006686A2
BR112012006686A2 BR112012006686A BR112012006686A BR112012006686A2 BR 112012006686 A2 BR112012006686 A2 BR 112012006686A2 BR 112012006686 A BR112012006686 A BR 112012006686A BR 112012006686 A BR112012006686 A BR 112012006686A BR 112012006686 A2 BR112012006686 A2 BR 112012006686A2
Authority
BR
Brazil
Prior art keywords
amide compound
substituted amide
substituted
compound
amide
Prior art date
Application number
BR112012006686A
Other languages
English (en)
Other versions
BR112012006686B1 (pt
BR112012006686B8 (pt
Inventor
Eiji Kawaminami
Hiroyuki Kaizawa
Kazuhiko Take
Kazuyuki Kuramoto
Kazuyuki Sakamoto
Ryushi Seo
Takatoshi Kanayama
Tatsuhisa Takahashi
Yuta Fukuda
Yutaka Kondoh
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BR112012006686A2 publication Critical patent/BR112012006686A2/pt
Publication of BR112012006686B1 publication Critical patent/BR112012006686B1/pt
Publication of BR112012006686B8 publication Critical patent/BR112012006686B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
BR112012006686A 2009-09-25 2010-09-24 compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa BR112012006686B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-220316 2009-09-25
JP2009220316 2009-09-25
PCT/JP2010/066572 WO2011037192A1 (ja) 2009-09-25 2010-09-24 置換アミド化合物

Publications (3)

Publication Number Publication Date
BR112012006686A2 true BR112012006686A2 (pt) 2016-05-10
BR112012006686B1 BR112012006686B1 (pt) 2021-02-09
BR112012006686B8 BR112012006686B8 (pt) 2021-05-25

Family

ID=43795936

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012006686A BR112012006686B8 (pt) 2009-09-25 2010-09-24 compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa
BR112013006936A BR112013006936A2 (pt) 2009-09-25 2011-09-22 composto de amida substituída

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013006936A BR112013006936A2 (pt) 2009-09-25 2011-09-22 composto de amida substituída

Country Status (17)

Country Link
US (2) US8669246B2 (pt)
EP (1) EP2481725B1 (pt)
JP (1) JP5708936B2 (pt)
KR (1) KR101678255B1 (pt)
CN (1) CN102548965B (pt)
AU (1) AU2010299114A1 (pt)
BR (2) BR112012006686B8 (pt)
CA (1) CA2774647C (pt)
ES (1) ES2532866T3 (pt)
IL (1) IL218723A0 (pt)
MX (1) MX2012003560A (pt)
PL (1) PL2481725T3 (pt)
PT (2) PT2481725E (pt)
RU (2) RU2609021C2 (pt)
TW (1) TW201117809A (pt)
WO (1) WO2011037192A1 (pt)
ZA (1) ZA201202106B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010299114A1 (en) 2009-09-25 2012-04-12 Astellas Pharma Inc. Substituted amide compound
WO2012039460A1 (ja) * 2010-09-24 2012-03-29 アステラス製薬株式会社 置換アミド化合物
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
AU2012296662A1 (en) 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
JP6058023B2 (ja) * 2011-12-15 2017-01-11 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ スルホンアミド誘導体
MX2014014234A (es) 2012-05-22 2015-05-07 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor.
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
CN103102325B (zh) * 2013-01-16 2014-11-12 浙江大学宁波理工学院 一种2-溴代甲基-4-羧酸乙酯噻唑的合成方法
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
RU2015143834A (ru) 2013-03-15 2017-04-24 Дженентек, Инк. Замещенные бензоксазолы и способы их применения
CN103467281B (zh) * 2013-07-25 2016-03-23 武汉英纳氏药业有限公司 一种苯酚衍生物及其应用
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
EP3074377B1 (en) 2013-11-27 2018-10-17 Genentech, Inc. Substituted benzamides and methods of use thereof
CA2935077C (en) * 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
EP3733209A1 (en) * 2014-10-03 2020-11-04 Synaffix B.V. Sulfamide linker, conjugates thereof, and methods of preparation
MX2017014715A (es) 2015-05-22 2018-03-16 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas.
CN106243003B (zh) * 2015-06-03 2018-03-09 上海海雁医药科技有限公司 环烃基取代的甲磺酰基苯甲酰胺衍生物、其制法与医药上的用途
US10253131B2 (en) * 2015-07-13 2019-04-09 University Of Delaware Polymers prepared from functionalized dimethoxyphenol monomers
US11525024B2 (en) 2015-07-13 2022-12-13 University Of Delaware Bio-based polymers from raw lignocellulosic biomass
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
CN105085245A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氟扁桃酸的制备方法
CN105085235A (zh) * 2015-08-31 2015-11-25 彭静 拆分制备s-4-氯扁桃酸的方法
CN105152913A (zh) * 2015-08-31 2015-12-16 彭静 S-4-氟扁桃酸的制备方法
CN105085244A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-溴苦杏仁酸的制备方法
CN105085234A (zh) * 2015-08-31 2015-11-25 彭静 一种r-4-氯扁桃酸的制备方法
CN105085246A (zh) * 2015-09-02 2015-11-25 彭静 一种r-邻氯扁桃酸的制备方法
CN105085248A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备s-4-甲氧基扁桃酸的方法
CN105085247A (zh) * 2015-09-02 2015-11-25 彭静 拆分制备r-4-甲氧基扁桃酸的方法
CN105061190A (zh) * 2015-09-02 2015-11-18 彭静 拆分制备s-五氟苦杏仁酸的方法
CN105085236A (zh) * 2015-09-02 2015-11-25 彭静 R-五氟苦杏仁酸的拆分制备方法
CA2999769A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
MA43304A (fr) 2015-11-25 2018-10-03 Genentech Inc Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
EP3413915A1 (en) 2016-02-08 2018-12-19 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting her2 tumours and method for improving therapeutic index of antibody-conjugates
CN109152844B (zh) 2016-02-08 2022-11-22 西纳福克斯股份有限公司 用于治疗的含有磺酰胺接头的生物缀合物
EP3413922A1 (en) * 2016-02-08 2018-12-19 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
SG11201903348UA (en) 2016-10-17 2019-05-30 Genentech Inc Therapeutic compounds and methods of use thereof
WO2018175707A1 (en) 2017-03-24 2018-09-27 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
CN112236424B (zh) * 2018-06-07 2024-03-15 爱杜西亚药品有限公司 经烷氧基取代的吡啶基衍生物
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
JPWO2021029311A1 (pt) 2019-08-09 2021-02-18
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
KR20230019880A (ko) 2020-06-03 2023-02-09 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9794598A (en) 1997-10-10 1999-05-03 Lxr Biotechnology Inc. Methods for detecting compounds which modulate the activity of an lpa receptor
AU2001232340A1 (en) 2000-02-18 2001-08-27 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
AU2003241833A1 (en) 2002-05-28 2003-12-12 Ono Pharmaceutical Co., Ltd. Beta-ALANINE DERIVATIVE AND USE THEREOF
US7300917B2 (en) 2002-06-26 2007-11-27 Ono Pharmaceuticals Co., Ltd. Remedy for chronic disease
US7294642B2 (en) * 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
EP1695955B1 (en) * 2003-12-19 2011-10-12 Ono Pharmaceutical Co., Ltd. Compounds having lysophosphatidic acid receptor antagonism and uses thereof
JP5315611B2 (ja) * 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
US7626039B2 (en) * 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
AU2009310374B2 (en) 2008-03-03 2014-06-19 Rxbio, Inc. LPA receptor agonists and antagonists
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
AU2010299114A1 (en) 2009-09-25 2012-04-12 Astellas Pharma Inc. Substituted amide compound
WO2012039460A1 (ja) * 2010-09-24 2012-03-29 アステラス製薬株式会社 置換アミド化合物

Also Published As

Publication number Publication date
CN102548965B (zh) 2014-04-09
RU2609021C2 (ru) 2017-01-30
CA2774647A1 (en) 2011-03-31
AU2010299114A1 (en) 2012-04-12
BR112012006686B1 (pt) 2021-02-09
US8669246B2 (en) 2014-03-11
RU2012116505A (ru) 2013-11-20
US8815920B2 (en) 2014-08-26
BR112012006686B8 (pt) 2021-05-25
BR112013006936A2 (pt) 2016-07-19
WO2011037192A1 (ja) 2011-03-31
RU2563639C2 (ru) 2015-09-20
KR101678255B1 (ko) 2016-11-21
CA2774647C (en) 2017-03-28
TW201117809A (en) 2011-06-01
RU2015117267A (ru) 2015-11-10
US20120184521A1 (en) 2012-07-19
MX2012003560A (es) 2012-10-05
PL2481725T3 (pl) 2015-08-31
KR20120078700A (ko) 2012-07-10
ES2532866T3 (es) 2015-04-01
ZA201202106B (en) 2013-05-29
CN102548965A (zh) 2012-07-04
JP5708936B2 (ja) 2015-04-30
EP2481725A4 (en) 2013-03-20
US20130231320A1 (en) 2013-09-05
PT2481725E (pt) 2015-05-21
EP2481725B1 (en) 2015-03-04
JPWO2011037192A1 (ja) 2013-02-21
PT2620433E (pt) 2015-06-22
IL218723A0 (en) 2012-06-28
EP2481725A1 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
BR112012006686A2 (pt) composto amida substituído
CY2017026I2 (el) Τετρακυκλικη ενωση
BRPI0912778A2 (pt) composto de amida
SMT201600008B (it) Composti di piridazinone
BRPI1013868A2 (pt) composto diaciletilenodiamina
BR112012006859A2 (pt) compostos
DK2427449T3 (da) Vinylindazolylforbindelser
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
BRPI1008774A2 (pt) espiroamida substituída
DK2421861T3 (da) Faste former af en azocyklisk amid
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
DOP2012000224A (es) Compuesto heterociclico
BRPI1005525A2 (pt) compostos de azaazuleno
BR112012008061A2 (pt) compostos de oxima heterocíclica
BRPI1009287A2 (pt) composto de quinoxalina
UY33156A (es) Nuevos compuestos tienopirrol
PL2620433T3 (pl) Podstawiony związek amidowy
BRPI0923592A2 (pt) composto
BRPI1010198A2 (pt) composição de poliamida modificada
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida
BR112012026803A2 (pt) composto
BR112012009784A2 (pt) composto benzazepínico
BRPI0909461A2 (pt) Composto de enaminotiocarbonila substituídos
ES1070429Y (es) Traspaleta mejorada
DK2623492T3 (da) Cyclohexanderivatforbindelse

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF